Illumina’s Alliance for Genomic Discovery expanded its roster of industry partners—adding Alnylam Pharmaceuticals among others—and now includes more than 250,000 sequenced genomes from Vanderbilt’s BioVU biobank linked to electronic health records. Company spokespeople and partner executives told reporters the dataset’s size and linked clinical data attract pharma firms hunting genetically validated targets, real‑world evidence, and translational insights. Illumina is positioning the Alliance as an end‑to‑end demonstration of its sequencing and analytics stack, with plans to add proteomic and other modalities. Partners report using the resource across target discovery, clinical development hypothesis generation, and real‑world data explorations. Illumina’s effort underscores growing industry demand for large, deeply phenotyped genomic cohorts to de‑risk target selection for modalities ranging from RNA therapeutics to gene editing.